ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,235.48
      -0.60%
      US Tech 100
      18,017.60
      -1.31%
      Dow Jones
      38,111.48
      -0.86%
      Brent Oil
      81.735
      -0.26%
      Bitcoin
      68,363.53
      0.00%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Cryptocurrencies
      4. COIN
      5. (Cryptocurrency:GNCCGBP)

      6. (Cryptocurrency:GNCCGBP) News

      GNCCGBP

      (GNCCGBP)

      Unknown symbol
      		Date:
      Sort by:
      DateTimeSourceHeadlineSymbolCompany
      5:18PMiHub NewswireFeaturedElement79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4
      05/31/20241:07AMAlliance NewsAlliance NewsJapan's monthly retail sales rebound in April; unemployment stable
      05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOBIT:1SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Net asset value of the EfTEN United Property Fund as of 30.04.2024
      05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDBIT:SANFSanofi
      05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOBIT:SANFSanofi
      05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDBIT:1SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOTG:SNWSanofi
      05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDTG:SNWSanofi
      05/31/20241:05AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDNASDAQ:REGNRegeneron Pharmaceuticals Inc
      05/31/20241:05AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDEU:SANSanofi
      05/31/20241:05AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDNASDAQ:SNYSanofi
      05/31/20241:00AMGlobeNewswire Inc.VEON discloses April YTD trading update at its AGMEU:VEONVEON Ltd
      05/31/20241:00AMBusiness WireElliptic Labs Launching on Upcoming vivo S19 and S19 Pro Smartphones
      05/31/20241:00AMGlobeNewswire Inc.Issue of Additional Tier 1 Temporary Write-Down Notes
      05/31/20241:00AMGlobeNewswire Inc.VEON discloses April YTD trading update at its AGMLSE:0RO7Veon Ltd
      05/31/20241:00AMGlobeNewswire Inc.Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024NASDAQ:ADXNAddex Therapeutics Ltd
      05/31/20241:00AMGlobeNewswire Inc.VEON discloses April YTD trading update at its AGMNASDAQ:VEONVEON Ltd
      05/31/20241:00AMGlobeNewswire Inc.VEON discloses April YTD trading update at its AGMTG:35V1VEON Ltd
      05/31/20241:00AMGlobeNewswire Inc.BioSenic S.A. : Information relative au nombre total de droits de vote et d’actionsLSE:0R55Biosenic Sa
      05/31/20241:00AMGlobeNewswire Inc.BioSenic S.A. : Information on the total number of voting rights and sharesLSE:0R55Biosenic Sa
      05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
      05/31/20241:00AMGlobeNewswire Inc.Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationNASDAQ:SNYSanofi
      05/31/20241:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2EU:SANSanofi
      05/31/20241:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2BIT:SANFSanofi
      05/31/20241:00AMGlobeNewswire Inc.Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationEU:SANSanofi
      05/31/20241:00AMGlobeNewswire Inc.Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2BIT:1SANSanofi